Azenta Enhances Global Biorepository Services with UK Biocentre Acquisition

Azenta Acquires UK Biocentre: A Milestone for Biorepository Services

In a strategic move aimed at expanding its footprint, Azenta, Inc. has successfully completed the acquisition of UK Biocentre Limited, a prominent service provider in sample management and high-throughput processing in the United Kingdom. With a deal valued at £20.5 million, including potential earn-out provisions, this acquisition is set to significantly enhance Azenta's biorepository offerings in Europe.

Strategic Importance of the Acquisition

The integration of UK Biocentre into Azenta's operations is poised to reinforce the company's capacity in providing comprehensive lifecycle solutions in biorepository services. As life science research hubs increasingly emerge in the UK, this move underscores Azenta’s commitment to solidifying its position within the European market. The new acquisition will operate under its existing brand, creating a seamless transition and continuity for existing clients in the pharmaceutical, biotechnology, and academic sectors.

Gregory Jones, the Chief Operating Officer of Azenta, characterized this acquisition as a pivotal step toward enhancing global sample management capabilities. By establishing UK Biocentre as a central operating hub, Azenta aims to broaden its reach and service offerings across Europe, thereby supporting an extensive client base with high-quality, integrated sample management solutions.

UK Biocentre’s Role and Impact

Founded in 2014, UK Biocentre has established itself as an essential partner in critical biomedical and pharmaceutical studies, facilitating projects that lead to groundbreaking discoveries. The organization reported revenues of approximately £15.3 million for the fiscal year ending September 30, 2025, showcasing its strength and stability in a competitive market.

The acquisition is expected to not only maintain but also enhance revenue growth for Azenta. Pro forma projections indicate a slight dilutive effect on adjusted EBITDA margins for 2026, but it should be accretive to revenue growth and margin expectations in subsequent years. The expanded capabilities are anticipated to include the deployment of Azenta's state-of-the-art BioArc™ Ultra, capable of managing up to 16 million samples, thereby increasing high-throughput capacity.

Leadership Perspectives

John Marotta, President and CEO of Azenta, emphasized that this acquisition strategically positions the company at the nexus of vital workflows within the life sciences ecosystem. He noted that the operational synergy gained through this purchase will enhance Azenta's service platform with significant operational expertise, enabling it to deliver scalable biorepository capabilities effectively.

Dr. Tony Cox OBE, CEO of UK Biocentre, also expressed enthusiasm about the merger, highlighting how the partnership with a global leader like Azenta would catalyze growth, improve infrastructure, and enhance service offerings across various scientific communities. He reiterated their ongoing commitment to scientific excellence and innovation, which will now be supported by Azenta’s extensive resources.

Looking Ahead: The Future of Biorepository Services

As life sciences continue to evolve, the need for robust sample management solutions becomes increasingly critical. This acquisition represents not just an expansion of facilities and capabilities but also a commitment to advancing research in biomedicine on a broader scale. With Azenta's capabilities enhancing UK Biocentre’s already strong platform, both organizations are poised for a promising future that will benefit researchers and developers across multiple domains.

Azenta will host a conference call on March 10, 2026, to further discuss the implications of this acquisition and its impact on future operations. As the life sciences sector continues to grow, this acquisition positions Azenta strategically to meet the demands of tomorrow’s scientific challenges, ensuring enhanced delivery of innovative therapies and solutions to the market.

Through strategic acquisitions like that of UK Biocentre, Azenta is not just investing in its corporate growth but also in the future of scientific research and discovery, paving the way for ongoing advancements in life sciences.